Zobrazeno 1 - 10
of 706
pro vyhledávání: '"B. Groot-Koerkamp"'
Autor:
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polée, H. C. van Santvoort, J. de Vos – Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvan
Externí odkaz:
https://doaj.org/article/9bd0b84a5c244ba18797a99563ce5af4
Autor:
D. Doppenberg, M. G. Besselink, C. H. J. van Eijck, M. P. W. Intven, B. Groot Koerkamp, G. Kazemier, H. W. M. van Laarhoven, M. Meijerink, I. Q. Molenaar, J. J. M. E. Nuyttens, R. van Os, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, E. Versteijne, J. W. Wilmink, F. J. Lagerwaard, A. M. E. Bruynzeel
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently
Externí odkaz:
https://doaj.org/article/c73bd68aed71460cbe9d36d02915a990
Autor:
I. W. J. M. van Goor, L. A. Daamen, M. G. Besselink, A. M. E. Bruynzeel, O. R. Busch, G. A. Cirkel, B. Groot Koerkamp, N. Haj Mohammed, H. D. Heerkens, H. W. M. van Laarhoven, G. J. Meijer, J. Nuyttens, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, J. W. Wilmink, I. Q. Molenaar, M. P. W. Intven, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20–30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stere
Externí odkaz:
https://doaj.org/article/8a61da727e0c449d953316f7b4843f0c
Autor:
F. L. Vissers, A. Balduzzi, E. A. van Bodegraven, J. van Hilst, S. Festen, M. Abu Hilal, H. J. Asbun, J. S. D. Mieog, B. Groot Koerkamp, O. R. Busch, F. Daams, M. Luyer, M. De Pastena, G. Malleo, G. Marchegiani, J. Klaase, I. Q. Molenaar, R. Salvia, H. C. van Santvoort, M. Stommel, D. Lips, M. Coolsen, C. Bassi, C. van Eijck, M. G. Besselink, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Prophylactic abdominal drainage is current standard practice after distal pancreatectomy (DP), with the aim to divert pancreatic fluid in case of a postoperative pancreatic fistula (POPF) aimed to prevent further complications as
Externí odkaz:
https://doaj.org/article/82d650d3833548f9abee78ebd8fbb9ad
Autor:
F. L. Vissers, A. Balduzzi, E. A. van Bodegraven, J. van Hilst, S. Festen, M. Abu Hilal, H. J. Asbun, J. S. D. Mieog, B. Groot Koerkamp, O. R. Busch, F. Daams, M. Luyer, M. De Pastena, G. Malleo, G. Marchegiani, J. Klaase, I. Q. Molenaar, R. Salvia, H. C. van Santvoort, M. Stommel, D. Lips, M. Coolsen, C. Bassi, C. van Eijck, M. G. Besselink, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/4dadcf422f1543d6a9bab5a6f614bf21
Autor:
Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. de Vos-Geelen, B. M. Zonderhuis, M. Y. V. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are hi
Externí odkaz:
https://doaj.org/article/c4666a70be2f4516b363089ddb9e6b2b
Autor:
M. W. Steen, L. B. vanRijssen, S. Festen, O. R. Busch, B. Groot Koerkamp, L. G. van derGeest, I. H. deHingh, H. C. vanSantvoort, M. G. Besselink, M. F. Gerhards, Dutch Pancreatic Cancer Group
Publikováno v:
BJS Open, Vol 4, Iss 5, Pp 884-892 (2020)
Background Dutch guidelines indicate that treatment of pancreatic head and periampullary malignancies should be started within 3 weeks of the multidisciplinary team (MDT) meeting. This study aimed to assess the impact of time to surgery on oncologica
Externí odkaz:
https://doaj.org/article/fd040b2597ce4f55933deec353cbf6ee
Autor:
F. Jasmijn Smits, Anne Claire Henry, Casper H. van Eijck, Marc G. Besselink, Olivier R. Busch, Mark Arntz, Thomas L. Bollen, Otto M. van Delden, Daniel van den Heuvel, Christiaan van der Leij, Krijn P. van Lienden, Adriaan Moelker, Bert A. Bonsing, Inne H. M. Borel Rinkes, Koop Bosscha, R. M. van Dam, Sebastiaan Festen, B. Groot Koerkamp, Erwin van der Harst, Ignace H. de Hingh, Geert Kazemier, Mike Liem, B. Marion van der Kolk, Vincent E. de Meijer, Gijs A. Patijn, Daphne Roos, Jennifer M. Schreinemakers, Fennie Wit, C. Henri van Werkhoven, I. Quintus Molenaar, Hjalmar C. van Santvoort, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-16 (2020)
Abstract Background Pancreatic resection is a major abdominal operation with 50% risk of postoperative complications. A common complication is pancreatic fistula, which may have severe clinical consequences such as postoperative bleeding, organ failu
Externí odkaz:
https://doaj.org/article/2c3622f1841e47eeb63fad385131042d
Autor:
I. W. J. M. van Goor, L. A. Daamen, M. G. Besselink, A. M. E. Bruynzeel, O. R. Busch, G. A. Cirkel, B. Groot Koerkamp, N. Haj Mohammed, H. D. Heerkens, H. W. M. van Laarhoven, G. J. Meijer, J. Nuyttens, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, J. W. Wilmink, I. Q. Molenaar, M. P. W. Intven, for the Dutch Pancreatic Cancer Group
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/571102f0d4bd4efab83c4ed6445894c5
Autor:
D. Doppenberg, M. G. Besselink, C. H. J. van Eijck, M. P. W. Intven, B. Groot Koerkamp, G. Kazemier, H. W. M. van Laarhoven, M. Meijerink, I. Q. Molenaar, J. J. M. E. Nuyttens, R. van Os, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, E. Versteijne, J. W. Wilmink, F. J. Lagerwaard, A. M. E. Bruynzeel, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/14805f39cbc942038bc7585cd8b7fee5